Siao Ping Tsai
Overview
Explore the profile of Siao Ping Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kajihara K, Pantua H, Hernandez-Barry H, Hazen M, Deshmukh K, Chiang N, et al.
mBio
. 2021 Jun;
12(3):e0020221.
PMID: 34061593
Pseudomonas aeruginosa causes life-threatening infections that are associated with antibiotic failure. Previously, we identified the antibiotic G2637, an analog of arylomycin, targeting bacterial type I signal peptidase, which has moderate...
2.
Fourie-ODonohue A, Chu P, Dela Cruz Chuh J, Tchelepi R, Tsai S, Tran J, et al.
MAbs
. 2020 Jan;
12(1):1715705.
PMID: 31997712
For antibody-drug conjugates to be efficacious and safe, they must be stable in circulation to carry the payload to the site of the targeted cell. Several components of a drug-conjugated...
3.
Scales S, Tsai S, Zacharias N, Dela Cruz-Chuh J, Bullen G, Velasquez E, et al.
Bioconjug Chem
. 2019 Nov;
30(12):3046-3056.
PMID: 31726009
Disulfide-linked bioconjugates allow the delivery of pharmacologically active or other cargo to specific tissues in a redox-sensitive fashion. However, an understanding of the kinetics, subcellular distribution, and mechanism of disulfide...
4.
Lee B, Chalouni C, Doll S, Nalle S, Darwish M, Tsai S, et al.
Bioconjug Chem
. 2018 Jun;
29(7):2468-2477.
PMID: 29856915
Despite the recent success of antibody-drug conjugates (ADCs) in cancer therapy, a detailed understanding of their entry, trafficking, and metabolism in cancer cells is limited. To gain further insight into...
5.
Dominguez S, Hegde G, Hanson J, Xiang H, Mandikian D, Boswell C, et al.
Sci Rep
. 2018 May;
8(1):8239.
PMID: 29844389
Neuregulin 1 (NRG1) is required for development of the central and peripheral nervous system and regulates neurotransmission in the adult. NRG1 and the gene encoding its receptor, ERBB4, are risk...
6.
Ohri R, Bhakta S, Fourie-ODonohue A, Dela Cruz-Chuh J, Tsai S, Cook R, et al.
Bioconjug Chem
. 2018 Feb;
29(2):473-485.
PMID: 29425028
THIOMAB antibody technology utilizes cysteine residues engineered onto an antibody to allow for site-specific conjugation. The technology has enabled the exploration of different attachment sites on the antibody in combination...
7.
Wei B, Gunzner-Toste J, Yao H, Wang T, Wang J, Xu Z, et al.
J Med Chem
. 2017 Dec;
61(3):989-1000.
PMID: 29227683
Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC...
8.
Couch J, Zhang G, Beyer J, Zuch de Zafra C, Gupta P, Kamath A, et al.
Clin Cancer Res
. 2015 Nov;
22(6):1469-79.
PMID: 26589434
Purpose: Although agents targeting Delta-like ligand 4 (DLL4) have shown great promise for angiogenesis-based cancer therapy, findings in recent studies have raised serious safety concerns. To further evaluate the potential...
9.
Lin K, Rubinfeld B, Zhang C, Firestein R, Harstad E, Roth L, et al.
Clin Cancer Res
. 2015 Jul;
21(22):5139-50.
PMID: 26156394
Purpose: Antibody-drug conjugates (ADC) selectively deliver a cytotoxic drug to cells expressing an accessible antigenic target. Here, we have appended monomethyl auristatin E (MMAE) to an antibody recognizing the SLC34A2...
10.
Kamath A, Yip V, Gupta P, Boswell C, Bumbaca D, Haughney P, et al.
MAbs
. 2014 Dec;
6(6):1631-7.
PMID: 25484068
Delta-like-4 ligand (DLL4) plays an important role in vascular development and is widely expressed on the vasculature of normal and tumor tissues. Anti-DLL4 is a humanized IgG1 monoclonal antibody against...